Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 16, 2022

SELL
$3.38 - $5.65 $202,012 - $337,683
-59,767 Reduced 99.61%
233 $60 Million
Q2 2021

Aug 11, 2021

BUY
$9.4 - $16.85 $564,000 - $1.01 Million
60,000 New
60,000 $634,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track International Biotechnology Trust PLC Portfolio

Follow International Biotechnology Trust PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of International Biotechnology Trust PLC, based on Form 13F filings with the SEC.

News

Stay updated on International Biotechnology Trust PLC with notifications on news.